SLC5A2 and Hyperglycemia: A new class of antidiabetic agents, sodium/glucose cotransporter‐2 (SGLT2) inhibitors, reduces both hyperglycaemia and body weight (BW),12, 13 thereby lowering liver enzyme levels.14, 15